What happens in a phase 1 clinical trial?

In a phase 1 trial, researchers work out whether a new treatment is safe. The National Cancer Institute lists four questions it answers: what the side effects are, whether people can tolerate it, the highest dose people can tolerate, and whether the treatment affects the cancer.

The group is small, around 15 to 30 people.

Finding the dose is the whole job

Almost every cancer drug has a range where too little does nothing and too much causes harm. Nobody knows where that range sits in humans until a phase 1 trial establishes it.

So these studies are built around dose finding. A small first group receives a low dose and is watched closely. If nothing serious happens, the next group receives more. The pattern repeats until side effects reach a level that should not be exceeded, and the dose below that line goes forward into later testing.

That is why the group is so small, and why enrollment is slow and staggered. Each step waits on the results of the one before it.

What taking part involves

Expect more of everything than routine care involves. More clinic visits, more blood draws, more scans, more questions about symptoms. Monitoring is heavier by design, because detecting problems is the trial's purpose.

That intensity is worth thinking through in practical terms: travel, time off work, and whether someone else can drive.

NCI notes that the support offered varies by trial and may include communication with the existing care team, guidance on managing symptoms, reimbursement for time, coverage of travel, transportation and lodging costs, and even notes for an employer or school about missed days. It is equally clear that not all trials cover expenses, and that the study team goes over those details at pre-screening.

Be clear-eyed about the aim, too. A phase 1 trial asks whether a treatment is safe and at what dose. Personal benefit is possible, and it does happen, but it is not what the trial is designed to measure.

Where phase 1 sits

NCI describes four phases, and the split is simple. Early phases test safety. Later phases compare the treatment against what already exists.

• Phase 1 tests safety, side effects, tolerability, and dose in about 15 to 30 people.
• Phase 2 includes 50 to 100 people, to see whether the treatment seems to work against the cancer, such as by shrinking tumors or slowing their growth. Safety study continues here.
• Phase 3 compares the treatment against current standard therapy in 100 to several thousand people, with participants randomly assigned. Results from phases 1 to 3 are what agencies such as the FDA use to decide on approval.
• Phase 4 looks at long-term safety and effectiveness after approval, in large and diverse populations.

Depending on the results at each stage, a treatment may or may not move to the next one.

What to establish before joining

Pre-screening is the place for questions. Ask what is known so far about the drug and its side effects, how many visits are required, how long each takes, and for how many months.

Ask who pays for what, since study procedures and routine care are often billed differently, and ask what support the trial provides. Ask what happens after hours if a bad reaction occurs, and who to call.

Ask whether there is a standard treatment that joining would mean giving up, and what the treating oncologist thinks of that trade.

And know the exit exists. NCI says a participant can leave a study at any time, even after signing the consent form. Our guide to clinical trial phases covers the sequence, and clinical trial screening visit: what to expect covers the visit that decides eligibility.

Sources

• https://www.cancer.gov/research/participate/clinical-trials/how-trials-work
• https://www.cancer.gov/research/participate/clinical-trials/what-to-expect
• https://www.cancer.gov/research/participate/clinical-trials/safety